JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(2):108-113 | DOI: 10.36290/csf.2025.015

Resources and drug information on pharmacotherapy in pregnancy

Kateřina Malá-Ládová1, Eliška Rožníčková1, Petra Rozsívalová1, 2
1 Katedra sociální a klinické farmacie, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova Hradec Králové
2 Oddělení klinické farmacie, Nemocniční lékárna, Fakultní nemocnice Hradec Králové

Pregnancy is a unique period requiring careful assessment of safety and effectiveness of pharmacotherapeutic interventions regarding the mother and foetus. The main source of information on the choice of a drug in pregnancy is usually the summary of product information, which often offers only brief general information and encourages excessive caution. The aim of this article is therefore a narrative overview of available professional information resources on medication use during pregnancy, which can be utilized in the care of pregnant women taking medicines. It demonstrates national and international monographs, biomedical databases, clinical guidelines, specialized professional web portals for healthcare professionals, adverse drug reaction reporting databases, teratology information services, and congenital anomaly registries. The article also emphasizes that a comprehensive approach including systematic utilization of all available information sources to healthcare professional, multidisciplinary cooperation and applying evidence-based medicine principles are essential when searching for and critically evaluating information use in pregnancy.

Keywords: adverse drug reactions, drug safety in pregnancy, drug information centre, professional information resources, teratology information services.

Accepted: May 28, 2025; Published: June 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malá-Ládová K, Rožníčková E, Rozsívalová P. Resources and drug information on pharmacotherapy in pregnancy. Čes. slov. farm. 2025;74(2):108-113. doi: 10.36290/csf.2025.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 18.6.2026

    References

    1. Binder T. Farmakoterapie v graviditě. Klin Farmakol Farm. 2019;33(4):12-9. Go to original source...
    2. Vachek J, Tesař V, Zakyianov O, et al. Farmakoterapie v těhotenství a při kojení. 2. vydání. Praha: Maxdorf Jesenius; 2016.
    3. Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014 Apr 3;5:65. Go to original source... Go to PubMed...
    4. Kaye DK. The moral imperative to approve pregnant women's participation in randomized clinical trials for pregnancy and newborn complications. Philos Ethics Humanit Med. 2019 Sep 6;14(1):11. Go to original source... Go to PubMed...
    5. Hunt A, Banner N, Littler K. The global forum on bioethics in research meeting, "ethics of research in pregnancy": emerging consensus themes and outputs. Reprod Health. 2017 Dec 14;14(Suppl 3):158. Go to original source... Go to PubMed...
    6. Rožníčková E. Analýza dotazů lékového informačního centra zaměřených na farmakoterapii u těhotných a kojících žen. Hradec Králové: Univerzita Karlova, Farmaceutická fakulta v Hradci Králové; 2023.
    7. Benevent J, Araujo M, Hurault-Delarue C, et al. Pharmacoepidemiology in pregnancy. Therapie. 2019 Apr;74(2):289-300. Go to original source... Go to PubMed...
    8. Malone P, Kier KL, Stanovich JE, Malone MJ. Drug information: a guide for pharmacists. 5. edition. New York: Mc Graw Hill Education. 2014.
    9. Wood ME, Andrade SE, Toh S. Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research. Clin Ther. 2019 Dec;41(12):2467-76. Go to original source... Go to PubMed...
    10. Clinical Postapproval Pregnancy Safety. Studies Guidance for Industry. [Internet]. U.S. Department of Health and Human Services, Food and Drug Administration; c2019. [cit. 3. 2. 2025]. Available from: https://www.fda.gov/media/124746/download.
    11. VigiBase. [Internet]. Sweden: Uppsala Monitoring Centre; c2025. [cit. 3.2. 2025]. Available from: https://who-umc.org/vigibase.
    12. Další literatura u autorek a na www.csfarmacie.cz
    13. ENTIS. [Internet]. European Network of Teratology Information Services; c2025. [cit. 15. 1. 2025]. Available from: https://www.entis-org.eu.
    14. About OTIS. [Internet]. USA: Organisation of Teratology Information Specialists; c2025. [cit. 15. 1. 2025]. Available from: https://mothertobaby.org/about-otis.
    15. UKTIS - Evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy. [Internet]. United Kingdom Teratology Information Service; c2025. [cit. 26. 1. 2025]. Available from: https://uktis.org.
    16. Toxbase. [Internet]. United Kingdom: National Poisons Information Service; c2025. [cit. 22. 1. 2025]. Available from: https://www.toxbase.org.
    17. BUMPS - Best Use of Medicines in Pregnancy. [Internet]. United Kingdom Teratology Information Service; c2025. [cit. 7. 2. 2025]. Available from: https://www.medicinesinpregnancy.org.
    18. Česká teratologická informační služba (CZTIS). [Internet]. Praha, ČR: 3. lékařská fakulta Univerzity Karlovy; c2025. [cit. 22. 1. 2025]. Available from: https://www.lf3.cuni.cz/3LF-1393.html.
    19. Babyrisk. [Internet]. Sankt Petersburg, Russia: Babyrisk.ru; c2025. [cit. 28. 6. 2022]. Available from: https://babyrisk.ru.
    20. Le CRAT. [Internet]. Paris, France: Le Centre de Référence sur les Agents tératogènes; c2025. [cit. 7. 2. 2025]. Available from: https://www.lecrat.fr/.
    21. Embryotox. [Internet]. Berlin, Germany: Charité - Universitätsmedizin Berlin; c2025. [cit. 7. 2. 2025]. Available from: Embryotox - Startseite.
    22. Teratology Information Services of Lareb. [Internet]. Netherlands Pharmacovigilance Centre Lareb; c2025. [cit. 31. 1. 2025]. Available from: lareb.nl/en/pages/teratology-information-services-tis/.
    23. Pregnancy PV Toolkit. [Internet]. Netherlands Pharmacovigilance Centre Lareb; c2018. [cit. 31. 1. 2025]. Available from: https://www.lareb.nl/media/chqbxdag/lareb-toolkit-pregnancy-okt18-c1.pdf.
    24. MELINDA. [Internet]. Netherlands: Radboudumc; c2025. [cit. 31. 1. 2025]. Available from: https://melinda-dosing.com/.
    25. Trygg Mammamedisin. [Internet]. Norway: RELIS; c2025. [cit. 28. 6. 2022]. Available from: https://tryggmammamedisin.no/.
    26. MotherToBaby. [Internet]. USA: Organisation of Teratology Information Specialists; c2025. [cit. 28. 1. 2025]. Available from: https://mothertobaby.org/.
    27. Národní registr reprodukčního zdraví. [Internet]. Praha, ČR: Ústav zdravotnických informací a statistiky ČR; c2025. [cit. 15. 1. 2025]. Available from: https://www.uzis.cz/index.php?pg=registry-sber-dat--narodni-zdravotni-registry--narodni-registr-reprodukcniho-zdravi.
    28. Národný register vrodených chýb. [Internet]. Bratislava, SR: Národné centrum zdravotníckych informácií; c2025. [cit. 30. 4. 2025]. Available from: https://www.nczisk.sk/Registre/Narodne-zdravotne-registre/Pages/Narodny-register-pacientov-s-vrodenou-vyvojovou-chybou.aspx
    29. EUROCAT. [Internet]. European Union: European Commission; c2025. [cit. 15. 1. 2025]. Available from: https://eu-rd-platform.jrc.ec.europa.eu/eurocat_en.
    30. ICBDSR. [Internet]. International Clearinghouse for Birth Defects Surveillance and Research; c2025. [cit. 15. 1. 2025]. Available from: http://www.icbdsr.org.
    31. Briggs GG. Brigg´s Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 12. edition. Philadelphia, Pennsylvania: Wolters Kluwer Health; 2021.
    32. Ainsworth SS. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. 8. edition. Oxford: Oxford University Press; 2020. Go to original source...
    33. Mattison D, Halbert LA. Clinical Pharmacology During Pregnancy. 2. edition. New York: Elsevier Inc. 2021.
    34. Nelson-Piercy C. Handbook of Obstetric Medicine. 6. edition. Boca Raton, Florida: CRC Press; 2021. Go to original source...
    35. Schaefer C, Peters PWJ, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. 3. edition. London: Academic Press; 2015.
    36. Fait T, Zikán M, Mašata J. Moderní farmakoterapie v gynekologii a porodnictví. 4. vydání. Praha: Maxdorf; 2024.
    37. Tížková K. Tabulky léčiv v těhotenství a při kojení. 1. vydání. Praha: Maxdorf; 2023.
    38. Adámková V. Antibiotika a infekce v těhotenství a laktaci. 1. vydání. Praha: Grada; 2022.
    39. Binder T. Nemoci v těhotenství a řešení vybraných závažných peripartálních
    40. EudraVigilance: European database of suspected adverse durg reaction reports. [Internet]. European Union: European Medicine Agency; c2025. [cit. 3. 2. 2025]. Available from: https://www.adrreports.eu.
    41. stavů. 1. vydání. Praha: Grada; 2020.
    42. Prescribing medicines in pregnancy database. [Internet]. Australian Government: Department of Health; c2025. [cit. 4. 2. 2025]. Available from: https://www.tga.gov.au/products/medicines/find-information-about-medicine/prescribing-medicines-pregnancy-database.
    43. Health Professionals. [Internet]. Melbourne, Australia: The Royal Women's Hospital; c2025. [cit. 6. 2. 2025]. Available from: https://www.thewomens.org.au/health-professionals.
    44. SOMANZ Written Guidelines. [Internet]. Society of Obstetric Medicine of Australia and New Zealand; c2025. [cit. 5. 2. 2025]. Available from: https://www.somanz.org.
    45. Statements and guidelines directory. [Internet]. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists; c2025. [cit. 6. 2. 2025]. Available from: https://ranzcog.edu.au.
    46. Pregnancy and Lactation Labeling Resources. [Internet]. U. S. Food and Drug Administration; c2025. [cit. 30. 4. 2025]. Available from: https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-resources
    47. Doporučený postup léky v těhotenství. [Internet]. Praha, ČR: Česká lékárnická komora; c2025. [cit. 30. 4. 2025]. Available from: https://lekarnici.cz/wp-content/uploads/2025/03/DP-Leky-v-tehotenstvi-2025-03-21.pdf
    48. Cybele: For the most important people in the world: the unborn and the newborn. [Internet]. Leuven, Belgium: Cybele; c2025. [cit. 3. 2. 2025]. Available from: https://www.cybele.be.
    49. Infpreg: Kunskapscentrum för infektioner under graviditet. [Internet]. Stockholm, Sweden: Infpreg; c2025. [cit. 9. 2. 2025]. Available from: https://www.medscinet.se/InfPreg/default.aspx.
    50. Janusmed. [Internet]. Stockholm, Sweden: Janusmed; c2025. [cit. 4. 2. 2025]. Available from: https://janusmed.se/.
    51. Maternity and Infant Care (MIC) database. [Internet]. London, England: Midirs; c2025. [cit. 4. 2. 2025]. Available from: https://rcm.org.uk/midirs/midirs-maternity-and-infant-care/.
    52. TERIS - The Teratogen Information System. [Internet]. Washington, USA: Department of Environmental and Occupational Health Sciences; c2021. [cit. 9. 2. 2025]. Available from: https://deohs.washington.edu/teris.
    53. Lékové informační centrum FAF UK a FN HK. [Internet]. Hradec Králové, ČR: Univerzity Karlova, Farmaceutická fakulta v Hradci Králové; c2025. [cit. 9. 2. 2025]. Available from: https://www.faf.cuni.cz/LIC/.
    54. Questions to ask when giving advice on medicines in pregnancy. [Internet]. England: Specialist Pharmacy Service; c2025. [cit. 9. 2. 2025]. Available from: https://www.sps.nhs.uk/articles/questions-to-ask-and-information-to-collect-when-giving-advice-about-medicines-in-pregnancy/.
    55. Oddelenie klinickej farmakológie. [Internet]. Bratislava, SR: Univerzitná nemocnica Ružinov; c2025. [cit. 30. 4. 2025]. Available from: https://www.unb.sk/oddelenie-klinickej-farmakologie/.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.